Works matching IS 11727047 AND DT 2022 AND VI 36 AND IP 11

Results: 8
    1
    2
    3
    4
    5
    6

    The XINDI Study: A Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Safinamide as Add-On Therapy to Levodopa in Chinese Patients with Parkinson's Disease with Motor Fluctuations.

    Published in:
    CNS Drugs, 2022, v. 36, n. 11, p. 1217, doi. 10.1007/s40263-022-00958-6
    By:
    • Wei, Qianqian;
    • Tan, Yuyan;
    • Xu, Pingyi;
    • Tao, Enxiang;
    • Lu, Zuneng;
    • Pan, Xiaoping;
    • Wang, Baojun;
    • Liu, Chunfeng;
    • Dong, Xueshuang;
    • Tian, Yuling;
    • Sun, Xin;
    • Cattaneo, Carlo;
    • Chen, Shengdi;
    • Shang, Huifang;
    • the XINDI Study Investigators Group;
    • Wu, Yuncheng;
    • Geng, Deqin;
    • Hu, Xingyue;
    • Luo, Yongjie;
    • Zhou, Jie
    Publication type:
    Article
    7
    8

    The Safety of Deutetrabenazine for Chorea in Huntington Disease: An Open-Label Extension Study.

    Published in:
    CNS Drugs, 2022, v. 36, n. 11, p. 1207, doi. 10.1007/s40263-022-00956-8
    By:
    • Frank, Samuel;
    • Testa, Claudia;
    • Edmondson, Mary C.;
    • Goldstein, Jody;
    • Kayson, Elise;
    • Leavitt, Blair R.;
    • Oakes, David;
    • O'Neill, Christine;
    • Vaughan, Christina;
    • Whaley, Jacquelyn;
    • Gross, Nicholas;
    • Gordon, Mark Forrest;
    • Savola, Juha-Matti;
    • The Huntington Study Group/ARC-HD Investigators and Coordinators;
    • Stamler, David;
    • Bockus, Margaret;
    • Leyva, Stephanie;
    • Snively, Victoria;
    • Wong, Cynthia;
    • Mallonee, William M.
    Publication type:
    Article